Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

J&J Innovation Launches 17 Collaborations

6/22/2015

0 Comments

 
New Brunswick, NJ - Johnson & Johnson Innovation said it has launched 17 collaborations with research institutions and healthcare companies, bringing to more than 200 the total number of collaborations formed since its 2013 launch.
hnson & Johnson Innovation said today it has launched 17 collaborations with research institutions and healthcare companies, bringing to more than 200 the total number of collaborations formed since its 2013 launch.

The 17 include a research alliance for the Disease Interception Accelerator (DIA), created in February to identify disease root causes and enable the development of treatments.  DIA and J&J’s Janssen Pharmaceuticals will partner with Washington University immunologist Emil Unanue, M.D., on the accelerator's their first research alliance/collaboration, focused on intercepting type 1 diabetes before it begins. The partners will explore the role of antigen presenting cells in the initiation and progression of type 1 diabetes, J&J Innovation said.

In February, the research/advocacy group JDRF agreed to support DIA's approach of further identifying root causes of type 1 diabetes.

J&J Innovation said Janssen Biotech will initiate treatment-focused collaborations with:

  • Carna Biosciences and Janssen Biotech to further develop and commercialize small molecules from one of Carna’s kinase inhibitor programs.
  • Novo Nordisk to further develop the monoclonal antibody NNC-0142-0002 (formerly NN8555), an agonist of the natural-killer group 2, member D (NKG2D) receptor, as a potential first-in-class treatment for inflammatory bowel diseases, subject to Hart-Scott-Rodino Antitrust clearance. Janssenagreed to license the program from Novo Nordisk in May.



Another J&J entity, Jansssen Cilag Pty Ltd., will join with The University of Queensland, Australia, its main commercialization company UniQuest, and Janssen Research & Development to identify, develop, and commercialize small molecule modulators of a biological target implicated in ankylosing spondylitis


“We are committed to working with researchers around the world to push the boundaries of what science and medicine can achieve to transform healthcare,” Paul Stoffels, M.D., J&J CSO and worldwide chairman, pharmaceuticals, said in a statement.

Janssen also said it was starting two tool-focused collaborations. The company will team up with Emulate to deploy the Organs-on-Chips platform across specific Janssen R&D clinical research programs that include Lung-on-Chip to evaluate pulmonary thrombosis, Liver-on-Chip to predict liver toxicity. The technology is designed to reduce drug candidate attrition in human clinical trials and advance safer candidates.

Janssen and HiFiBiO will evaluate HiFiBiO’s single cell technology for genetically characterizing individual cells as a potential new antibody discovery platform. Validation activities include comparing a large repertoire of B-cell antibodies from a number of different tissues generated against a target antigen chosen by Janssen R&D, J&J Innovation said.

Three other Janssen entities are teaming up with partners that include:

  • Arcturus Therapeutics, which is joining Janssen Pharmaceuticals to discover, develop and commercialize RNA-based drug products for undisclosed diseases using Arcturus’ UNA Oligomer™ chemistry and LUNAR™ nanoparticle delivery platform. Arcturus’ website describes the company as an RNA therapeutics company specializing in treatments for rare disease.
  • BRIM Technology, which with Janssen Pharmaceutica NV will work to research, develop, and commercialize new therapies for dengue fever.
  • The University of the Witwatersrand in South Africa, which will collaborate with Janssen Sciences Ireland UC to explore the delivery of transcription activator–like effector nucleases (TALENs) targeting hepatitis B using viral and non-viral vectors.



The other two collaborations focus on identifying environmental factors for asthma (with the University of Arizona’s BIO5 Institute and Johnson & Johnson Consumer & Personal Products unit), and on improving orthopedic surgeries (with DePuy Synthes Products), in part through biomarker diagnostics.


J&J Innovation said five of the collaborations will focus globally with:
  • China-based global contract R&D service provider WuXi AppTec on new biopharma and consumer healthcare products developed in China but sourced and marketed globally.
  • The Lead Discovery Center in Dortmund, Germany, on identifying and advancing molecules with therapeutic potential developed by German research institutions and universities that also align with strategic areas of interest of Janssen R&D.
  • Toronto’s MaRS Innovation on identifying and advancing early-stage technologies of interest to J&J companies.



Another two of the collaborations were announced May 22 by Sweden’s Karolinska Institutet. J&J Innovation has established a hub at Karolinska to provide investment and access to resources and expertise for emerging life sciences companies in the Nordic region.


Also, Janssen Pharmaceutica has launched a Real World Evidence research program in which its researchers and those of Karolinska will study how patients respond to medicines and other interventions based on parameters that include clinical, quality-of-life, social, and economic criteria.

“Initial areas of focus are depression, prostate cancer, psoriasis, B-cell malignancies, and method development, with the ultimate goal of improving our understanding of medical interventions and treatment outcomes under real-world conditions,” J&J Innovation stated.

0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
10 West Lafayette Street
Trenton, NJ 08608-2002
609-858-9507